AR096839A1 - Proceso mejorado para la producción de anticuerpos monoclonales - Google Patents

Proceso mejorado para la producción de anticuerpos monoclonales

Info

Publication number
AR096839A1
AR096839A1 ARP140102519A ARP140102519A AR096839A1 AR 096839 A1 AR096839 A1 AR 096839A1 AR P140102519 A ARP140102519 A AR P140102519A AR P140102519 A ARP140102519 A AR P140102519A AR 096839 A1 AR096839 A1 AR 096839A1
Authority
AR
Argentina
Prior art keywords
improved process
production
monoclonal antibodies
provides
temperature
Prior art date
Application number
ARP140102519A
Other languages
English (en)
Inventor
Bandyopadhyay Sanjay
Patel Sanjay
Kumar Mendiratta Sanjeev
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR096839A1 publication Critical patent/AR096839A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente provee un proceso mejorado para obtener una cantidad sustancial de anticuerpos monoclonales con un perfil deseado de variantes cargadas. El proceso implica inicialmente cultivar células de mamíferos a una temperatura adecuada y posteriormente reducir la temperatura; opcionalmente, mediante la adición simultánea de aminoácido(s) adecuado(s) durante la producción de la molécula deseada. La presente también provee un anticuerpo que tiene un perfil deseado de glicanos, preparado con dicho proceso mejorado.
ARP140102519A 2013-07-06 2014-07-07 Proceso mejorado para la producción de anticuerpos monoclonales AR096839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2285MU2013 IN2013MU02285A (es) 2013-07-06 2014-07-07

Publications (1)

Publication Number Publication Date
AR096839A1 true AR096839A1 (es) 2016-02-03

Family

ID=51794933

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102519A AR096839A1 (es) 2013-07-06 2014-07-07 Proceso mejorado para la producción de anticuerpos monoclonales

Country Status (18)

Country Link
US (1) US20160215319A1 (es)
EP (1) EP3019528A1 (es)
JP (1) JP2016526385A (es)
CN (1) CN105431454A (es)
AR (1) AR096839A1 (es)
AU (1) AU2014288811B2 (es)
BR (1) BR112015032800A2 (es)
CA (1) CA2917484A1 (es)
EA (1) EA201690171A1 (es)
HK (1) HK1218297A1 (es)
IL (1) IL243011A0 (es)
IN (1) IN2013MU02285A (es)
MX (1) MX2016000123A (es)
NZ (1) NZ715246A (es)
SG (1) SG11201510342VA (es)
TW (1) TW201514305A (es)
WO (1) WO2015004679A1 (es)
ZA (1) ZA201509334B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
KR20180114966A (ko) * 2009-08-11 2018-10-19 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
US9045536B2 (en) * 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
MX2012012528A (es) * 2010-04-26 2012-11-23 Novartis Ag Proceso de cultivo celular mejorado.
AU2011350456B2 (en) * 2010-12-28 2016-05-26 Chugai Seiyaku Kabushiki Kaisha Animal cell culturing method
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity

Also Published As

Publication number Publication date
US20160215319A1 (en) 2016-07-28
JP2016526385A (ja) 2016-09-05
BR112015032800A2 (pt) 2017-07-25
AU2014288811B2 (en) 2017-06-08
SG11201510342VA (en) 2016-01-28
NZ715246A (en) 2017-07-28
WO2015004679A1 (en) 2015-01-15
ZA201509334B (en) 2017-03-29
IL243011A0 (en) 2016-03-31
IN2013MU02285A (es) 2015-06-19
HK1218297A1 (zh) 2017-02-10
EP3019528A1 (en) 2016-05-18
CN105431454A (zh) 2016-03-23
TW201514305A (zh) 2015-04-16
CA2917484A1 (en) 2015-01-15
AU2014288811A1 (en) 2016-01-28
EA201690171A1 (ru) 2016-06-30
MX2016000123A (es) 2016-07-14

Similar Documents

Publication Publication Date Title
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
AR096713A1 (es) Proceso de purificación para anticuerpos monoclonales
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR106201A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CR20150393A (es) Moleculas biespecíficas de union a antígeno activadoras de células t
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
AR091116A1 (es) Anticuerpos biespecificos y sus metodos de uso
CL2019002521A1 (es) Método para producir anticuerpos multiespecíficos.
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
GT201400045A (es) Anticuerpo anti-abtcr
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
CR20160147A (es) Formulaciones de anticuerpos
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
AR100255A1 (es) Un factor de secreción de proteínas con alta eficiencia secretora y un vector de expresión que lo comprende
MX2015010428A (es) Anticuerpos anti-her2 altamente galactosilados y sus usos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure